Welcome to our dedicated page for DECOY THERAPEUTICS news (Ticker: DCOY), a resource for investors and traders seeking the latest updates and insights on DECOY THERAPEUTICS stock.
Decoy Therapeutics Inc. develops preclinical peptide conjugate therapeutics built around Designable Multi-Antivirals, or D-MAVs, and its proprietary IMP3ACT platform. Company news centers on AI-enabled peptide design, rapid synthesis and manufacturing, respiratory-virus programs, and scientific presentations tied to pan-coronavirus and broad antiviral discovery efforts.
Recurring updates also include computational biology collaborations, non-dilutive program support, investor communications, capital-market actions, and Nasdaq listing-compliance matters. The company's public updates frame Decoy as a preclinical biotechnology issuer focused on respiratory viruses, with earlier company materials also referencing GI cancer pipeline work.
Decoy Therapeutics (Nasdaq: DCOY) will present at two Boston peptide therapeutics conferences the week of April 27, 2026. Executives and advisors will discuss computational peptide design, peptide conjugate antivirals, and share new preclinical D-MAV data. The company highlighted a Quantori partnership and its IMP3ACT platform supporting pan-coronavirus and tripledemic programs.
Decoy Therapeutics (Nasdaq: DCOY) said it has accelerated execution across strategy, science and capital markets, advancing its AI-enabled IMP³ACT platform and D-MAV antiviral pipeline toward clinical development.
Key updates include an AI partnership with Quantori + Google Cloud (25–100x compute), a Gates Foundation global access commitment, non-dilutive funding, and a Phase 1 targeted in 2027.
Decoy Therapeutics (Nasdaq: DCOY) will host a Virtual Investor Closing Bell event on Thursday, April 9, 2026 at 4:00 PM ET featuring CEO Rick Pierce.
Mr. Pierce will provide a corporate overview and business outlook for 2026, take live investor questions, and a replay will be available two hours after the presentation for 90 days on the company investor events page.
Decoy Therapeutics (Nasdaq: DCOY) announced it regained compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement) effective March 31, 2026. The company is reported to be in compliance with all other continued listing requirements, but will be subject to a Mandatory Panel Monitor for one year from that date.
If the Listing Qualifications Staff finds renewed noncompliance during the one-year monitoring period, Nasdaq may issue a delisting determination letter and the company could request a hearing with the Nasdaq Hearings Panel.
Decoy Therapeutics (Nasdaq: DCOY) announced a strategic partnership with Quantori, supported by funding from Google Cloud, to build a Google Cloud-native, AI-driven peptide design and molecular simulation platform.
The production-grade, GPU-accelerated platform will integrate folding models, molecular dynamics, and Decoy's IMP³ACT engine, targeting a ~25- to 100-fold increase in computational throughput to accelerate antiviral peptide discovery.
Decoy Therapeutics (NASDAQ: DCOY) will effect a 1-for-12 reverse stock split at 5:00 p.m. ET on March 6, 2026, with split-adjusted trading beginning March 9, 2026 under CUSIP 79400X602.
The split reduces outstanding shares from ~6.38 million to ~532,000 and is intended to help Decoy regain compliance with Nasdaq's $1.00 minimum closing bid requirement. Outstanding options, warrants, and plan reserves will be adjusted and fractional shares will be paid in cash.
Decoy Therapeutics (NASDAQ: DCOY) announced on Feb 11, 2026 that it joined the Webull Corporate Connect Service platform to provide an additional communication channel for shareholders and investors. The company said the portal will distribute corporate news, earnings reports, product updates, presentations and notifications to improve transparency and engagement.
Decoy Therapeutics (Nasdaq: DCOY) will present at the Corporate Connect Webinar Series hosted by Webull Financial on Tuesday, February 10, 2026 at 1:20 PM EST.
CEO Rick Pierce will give a brief corporate overview and highlight the company's new class of antiviral peptide conjugate therapeutics that target multiple viral pathogens.
Decoy Therapeutics (Nasdaq: DCOY) participated in a virtual investor "What This Means" segment on Feb. 4, 2026, detailing its Global Access Commitment Agreement (GACA) with the Gates Foundation.
The company described plans to develop a flexible, scalable manufacturing platform for peptide-conjugate antivirals using its IMP3ACT™ technology, validated by an intranasal pan-coronavirus fusion inhibitor funded under the same Gates Foundation grant.
Decoy Therapeutics (Nasdaq: DCOY) announced a Global Access Commitment Agreement with the Gates Foundation to fund development of a globally accessible, scalable peptide-conjugate manufacturing platform for antiviral therapeutics. The platform will be validated using Decoy's intranasal pan-coronavirus fusion inhibitor and built with U.S. and European contract manufacturers to enable rapid scale-up on standard peptide-synthesis machinery. Decoy expects to advance its lead pan-coronavirus antiviral to an IND filing within 12 months and progress programs for broad-acting flu/COVID-19/RSV antivirals and a peptide drug conjugate for GI cancers.